Literature DB >> 18582831

Intravenous colistimethate for multidrug-resistant Gram-negative bacteria.

Alexandre P Zavascki, Jian Li.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18582831     DOI： 10.1016/S1473-3099(08)70133-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  3 in total

1.  Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug.

Authors:  Alexandre P Zavascki; Jian Li; Roger L Nation; Silvana V Superti; Afonso L Barth; Larissa Lutz; Fabiano Ramos; Márcio M Boniatti; Luciano Z Goldani
Journal:  J Clin Microbiol       Date:  2009-07-08       Impact factor: 5.948

2.  Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii.

Authors:  M H Rigatto; V B Ribeiro; D Konzen; A P Zavascki
Journal:  Infection       Date:  2012-11-04       Impact factor: 3.553

3.  Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study.

Authors:  Vikas Gautam; Nusrat Shafiq; Johan W Mouton; Sameer Malhotra; Satinder Kaur; Pallab Ray
Journal:  Indian J Med Res       Date:  2018-04       Impact factor: 2.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.